These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 26635047)
1. [Analysis of MGMT methylation with the therascreen(®) MGMT Pyro(®) Kit (Qiagen). A method verification]. Luquain A; Magnin S; Guenat D; Prétet JL; Viennet G; Valmary-Degano S; Mougin C Ann Biol Clin (Paris); 2015; 73(6):665-70. PubMed ID: 26635047 [TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
3. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115 [TBL] [Abstract][Full Text] [Related]
4. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840 [TBL] [Abstract][Full Text] [Related]
5. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. Zhao H; Wang S; Song C; Zha Y; Li L World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166 [TBL] [Abstract][Full Text] [Related]
6. Treatment considerations for MGMT-unmethylated glioblastoma. Taylor JW; Schiff D Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859 [TBL] [Abstract][Full Text] [Related]
7. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646 [TBL] [Abstract][Full Text] [Related]
8. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970 [TBL] [Abstract][Full Text] [Related]
9. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
10. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398 [TBL] [Abstract][Full Text] [Related]
11. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
12. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W; Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
16. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Xie H; Tubbs R; Yang B Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756 [TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844 [TBL] [Abstract][Full Text] [Related]
18. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Xie H; Tubbs R; Yang B Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069 [TBL] [Abstract][Full Text] [Related]
19. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. Parkinson JF; Wheeler HR; Clarkson A; McKenzie CA; Biggs MT; Little NS; Cook RJ; Messina M; Robinson BG; McDonald KL J Neurooncol; 2008 Mar; 87(1):71-8. PubMed ID: 18004504 [TBL] [Abstract][Full Text] [Related]
20. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients. McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]